

TAKEDA ONCOLOGY IS COMMITTED TO THE ADVANCEMENT OF INNOVATIVE THERAPIES: ONCOLOGY DEVELOPMENT PIPELINE

PROGRAM	DESCRIPTION	DISEASE(S) UNDER INVESTIGATION	PHASE 1	PHASE 2	PHASE 3
BRENTUXIMAB VEDOTIN¹	CD30 Monoclonal Antibody Drug Conjugate	Hodgkin's Lymphoma, Peripheral T-Cell Lymphoma	█		
BRIGATINIB	Anaplastic Lymphoma Kinase Inhibitor	Non-Small Cell Lung Cancer	█		
IXAZOMIB	Proteasome Inhibitor	Multiple Myeloma	█		
PEVONEDISTAT (TAK-924)	NEDD8-Activating Enzyme Inhibitor	Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myelogenous Leukemia	█		
PONATINIB²	BCR-ABL Inhibitor	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia	█		
RELUGOLIX (TAK-385)³	GnRH Antagonist	Prostate Cancer	█		
VEDOLIZUMAB	Anti- α 4 β 7 Antibody	Graft versus Host Disease	█		
CABOZANTINIB⁴	VEGFR/RTK Inhibitor	Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer	█		
NIRAPARIB⁵	PARP 1/2 Inhibitor	Ovarian Cancer, Prostate Cancer	█		
SAPANISERTIB (TAK-228)	TORC1/TORC2 Inhibitor	Non-Small Cell Lung Cancer	█		
SIMUROSERTIB (TAK-931)	CDC7 Inhibitor	Squamous Non-Small Cell Lung Cancer	█		
TAK-079	Anti-CD38 Monoclonal Antibody	Multiple Myeloma	█		
TAK-788	EGFR/HER2 Exon 20 Inhibitor	Non-Small Cell Lung Cancer	█		
TAK-007⁶	CD19 CAR-NK	Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia	█		
TAK-164	Anti-GCC Antibody Drug Conjugate	Gastrointestinal Cancers	█		
TAK-169	CD38 Targeted Engineered Toxin Body	Multiple Myeloma	█		
TAK-252 / SL-279252⁷	Agonist Redirected Checkpoint Fusion Protein PD1/OX40L	Solid Tumors	█		
TAK-573	CD38 Attenukine	Multiple Myeloma, Solid Tumors	█		
TAK-981	SUMO Activating Enzyme Inhibitor	Non-Hodgkin's Lymphoma, Solid Tumors	█		

THE MOLECULES LISTED ABOVE ARE INVESTIGATIONAL AGENTS. SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED.

All programs have Global Development Rights unless otherwise noted.

¹ Brentuximab vedotin is co-developed by Takeda and Seattle Genetics, Inc. ² Takeda shares development rights with Incyte Corp. (Europe, Turkey and Israel) and Otsuka Pharm. (Asia Pacific territories). ³ Japan and Asian countries. In partnership with Myovant Sciences, Inc. ⁴ Japan Only. In partnership with Exelixis, Inc. ⁵ Niraparib is being developed under a licensing agreement with Tesaro, Inc. for all tumor types in Japan and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia. ⁶ Under licensing agreement and in collaboration with MD Anderson Cancer Center. ⁷ Takeda retains an option to develop TAK-252 / SL-279252 with Shattuck Labs.

OMS/PIP/19/0009a(1)a(1)
11/2019



ONCOLOGY

All trademarks are the property of their respective owners.
©2019 Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. All rights reserved.